TBPH — Theravance Biopharma Inc stock price, charts and financials

Latest market price

17.04

+0.01+0.06%

Overview Short InterestFilings

TBPHQT67Theravance Biopharma Inc·NASDAQ

Overview Short InterestFilings

17.04+0.06%

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

MESO+3.19%$14.87 FTRE+1.55%$20.28 NKTR+1.45%$68.36 GHRS+3.50%$28.72 RAPP+1.35%$41.95 AGIO+2.00%$33.61 ZBIO-1.08%$31.97 GPCR-1.13%$35.10

Snapshot

Index	-	P/E	16.87	EPS (ttm)	1.01	Insider Own	33.47%	Shs Outstand	51.83M	Perf Week	0.12%

Market Cap	883.15M	Forward P/E	9.14	EPS next Y	1.86	Insider Trans	-2.09%	Shs Float	48.48M	Perf Month	0.53%

Enterprise Value	523.15M	PEG	-	EPS next Q	0.24	Inst Own	-	Short Float	3.34%	Perf Quarter	1.97%

Income	54.00M	P/S	8.41	EPS this Y	186.09%	Inst Trans	-	Short Ratio	2.52	Perf Half Y	23.21%

Sales	105.00M	P/B	3.05	EPS next Y	-35.47%	ROA	11.45%	Short Interest	1.62M	Perf YTD	-8.93%

Book/sh	5.60	P/C	2.28	EPS next 5Y	-13.20%	ROE	19.40%	52W High	21.03 -18.97%	Perf Year	22.86%

Cash/sh	7.49	P/FCF	17.01	EPS past 3/5Y	-	ROIC	0.95%	52W Low	13.08 30.28%	Perf 3Y	73.35%

Dividend Est.	-	EV/EBITDA	7.69	Sales past 3/5Y	28.02% 8.25%	Gross Margin	89.40%	Volatility	0.21% 0.32%	Perf 5Y	99.30%

Dividend TTM	-	EV/Sales	4.98	EPS Y/Y TTM	187.83%	Oper. Margin	4.46%	ATR (14)	0.06	Perf 10Y	-41.94%

Dividend Ex-Date	-	Quick Ratio	13.54	Sales Y/Y TTM	64.06%	Profit Margin	51.58%	RSI (14)	56.22	Recom	2.94

Dividend Gr. 3/5Y	-	Current Ratio	13.54	EPS Q/Q	-110.19%	SMA20	0.03%	Beta	0.19	Target Price	17.00

Payout	0.00%	Debt/Eq	0.26	Sales Q/Q	-19.23%	SMA50	0.50%	Rel Volume	0.48	Prev Close	17.03

Employees	90	LT Debt/Eq	0.22	Earnings	Nov 10	SMA200	-1.03%	Avg Volume	645.23K	Price	17.04

IPO Date	May 16, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	-251.72% -7.84%	Net Debt/EBITDA	-2.65	Volume	306,932	Change	0.06%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-07-26	Downgrade	HC Wainwright & Co.	Buy → Neutral	$15 → $17
Jun-29-26	Downgrade	BTIG	Buy → Neutral
Jun-29-26	Downgrade	Jones Trading	Buy → Hold
Mar-05-26	Downgrade	Oppenheimer	Outperform → Perform
Mar-04-26	Downgrade	B. Riley Securities	Buy → Neutral	$14
Dec-03-25	Initiated	Oppenheimer	Outperform	$27
Nov-26-25	Reiterated	BTIG	Buy	$21 → $40
Nov-13-24	Reiterated	Leerink Partners	Market Perform	$14 → $10
Aug-06-24	Reiterated	HC Wainwright & Co.	Buy	$15
Aug-06-24	Downgrade	Leerink Partners	Outperform → Market Perform

Latest News· Times ET

Sep-09-26

Sep-09-2608:31AM

Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue?zacks.com

12:01AM

Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell?defenseworld.net

Aug-17-26

Aug-17-2611:49PM

Empowered Funds LLC Purchases Shares of 55,463 Theravance Biopharma, Inc. $TBPHdefenseworld.net

Aug-15-26

Aug-15-2603:07AM

TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholdersbusinesswire.com

Aug-11-26

Aug-11-2606:31AM

TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworkszacks.com

Aug-10-26

Aug-10-2604:35AM

Theravance Biopharma Q2 Adj. EPS $0.18 Beats $0.05 Estimate, Sales $20.731M Miss $21.600M EstimateBenzinga

04:30AM

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Updateprnewswire.com

Aug-07-26

Aug-07-2611:34PM

Theravance Biopharma, Inc. $TBPH Shares Acquired by Dimensional Fund Advisors LPdefenseworld.net

Jul-09-26

Jul-09-2611:00AM

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBPH, IRDM, LCII, and PATKgurufocus.com

Jul-07-26

Jul-07-2603:41AM

HC Wainwright & Co. Downgrades Theravance Biopharma to Neutral, Raises Price Target to $17Benzinga

Jul-01-26

Jul-01-2604:30AM

Here's Why Zymeworks Inc. Paid $929M For Theravance Biopharmaseekingalpha.com

Jun-30-26

Jun-30-2605:55AM

Theravance Stock Down 3% After Zymeworks Announces Buyoutzacks.com

Jun-29-26

Jun-29-2610:00AM

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH)gurufocus.com

10:00AM

Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders?gurufocus.com

07:19AM

TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholdersbusinesswire.com

Company

Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	105	107	64	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	11	6	38	—	—	—	—	—	—
Gross Profit	93	102	27	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	52	74	69	—	—	—	—	—	—
Research and Development	26	37	38	—	—	—	—	—	—
Other Operating Expense	11	4	-33	—	—	—	—	—	—
Operating Income	5	-13	-47	—	—	—	—	—	—
Interest Expense	2	2	3	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	55	145	5	—	—	—	—	—	—
Net Income Before Taxes	59	129	-45	—	—	—	—	—	—
Income Taxes	4	23	12	—	—	—	—	—	—
Consolidated Net Income	54	106	-56	—	—	—	—	—	—
Net Income From Continuing Operations	54	106	-56	—	—	—	—	—	—
Net Income	54	106	-56	—	—	—	—	—	—
EPS (Recurring)	1.06	2.10	-1.15	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	1.06	2.10	-1.15	—	—	—	—	—	—
EPS (Diluted)	1.01	2.06	-1.15	—	—	—	—	—	—
EBITDA	68	137	-38	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	16.87	9.08	—	—	—	—	—	—	—
Price To Sales Ratio	8.44	8.74	7.20	—	—	—	—	—	—
Gross Margin	88.57	95.33	42.19	—	—	—	—	—	—
Operating Margin	4.76	-12.15	-73.44	—	—	—	—	—	—
Net Margin	51.43	99.07	-87.50	—	—	—	—	—	—
Shares Outstanding	52	50	49	—	—	—	—	—	—
Market Capitalization	886	936	461	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Sep 15 '26	Sale	17.03	13,314	226,794	213,476	Sep 17
Samaha Eli	10% Owner	Jul 01 '26	Sale	17.00	37,799	642,628	9,174,453	Jul 01
Samaha Eli	10% Owner	Jun 30 '26	Sale	17.13	25,027	428,788	9,212,252	Jul 01
Samaha Eli	10% Owner	Jun 29 '26	Sale	17.23	273,871	4,720,139	9,237,279	Jul 01
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Jun 15 '26	Sale	16.39	13,314	218,167	232,457	Jun 17
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Mar 16 '26	Sale	13.96	31,067	433,637	232,699	Mar 18
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Dec 03 '25	Sale	18.75	31,067	582,501	277,695	Dec 05
BROSHY ERAN	Director	Nov 26 '25	Sale	20.00	29,501	590,020	44,703	Dec 01
BROSHY ERAN	Director	Nov 26 '25	Option Exercise	10.15	14,000	142,100	81,749	Dec 01
BROSHY ERAN	Director	Nov 11 '25	Sale	18.05	104,000	1,877,500	46,204	Nov 14
BROSHY ERAN	Director	Nov 11 '25	Option Exercise	10.15	14,000	142,100	107,878	Nov 13
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Jul 14 '25	Sale	11.39	10,000	113,870	326,918	Jul 16
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Jun 02 '25	Sale	11.00	24,000	264,000	336,918	Jun 04
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Apr 21 '25	Sale	9.00	4,000	36,000	370,038	Apr 23
Farnum Rhonda	SVP, COMM & MEDICAL AFFAIRS	Jan 21 '25	Sale	9.00	4,000	36,000	309,565	Jan 23

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.